SWG Educational Activities


SWG AML Annual Scientific Meeting

The most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.

At EHA2023, our session focused on the:

  • New aspects in the 2022 ELN recommendations
  • Classification systems of AML

Joint AML/MDS/MPN meeting

We held a joint meeting with the:

This meeting, which was the first of its kind, was initially scheduled for 2021 but had to be postponed due to the COVID-19 pandemic.

The rescheduled event took place from November 2–4, 2023, in Budapest.

Attendees at this scientific meeting explored:

  • Commonalities and overlaps in myeloid malignancies
  • Important differences in the current understanding of the pathophysiology, novel treatments, and future of therapy in these diverse, yet interrelated, areas

19th ELN Symposium with 22nd KLN Symposium

This joint European LeukemiaNet (ELN) and Kompetenz Leukämienm (KLN) event took place on April 18, 2023.

Session two was on: ‘WP5 AML Clinical trials involving the SWG: Discussion on potential areas of collaboration between EHA and ELN AML working groups.’ The session was chaired by Gert Ossenkoppele and Christoph Röllig.

ELN Breakfast Meeting at the 65th ASH Annual Meeting

SWG members took part in this session, which was held on December 10, 2023, as part of the American Society for Hematology (ASH) Annual Meeting.

The topic was ‘WP5 AML1 and AML2, Emerging therapies.’

New manuscripts

In 2023, members of the SWG AML were actively involved in the creation of a new manuscript which provides:

  • Clinically relevant updates to the classification of myeloid neoplasms and acute leukemias
  • An overview of changes since the World Health Organization (WHO) 2017 ‘Blue Book’

In April 2024, the manuscript was announced in a HemaSphere editorial.

Collaborations on international projects promoted by/involving the SWG

We collaborated on joint HOVON-AMLSG clinical trials that included a large number of international cooperators and study groups.

You can find out more about this work on the websites of:

Translational work promoted by or involving the SWG

HARMONY projects

SWG members have been involved in projects on:

  • Measurable residual disease as surrogate marker for survival in AML
  • Optimizing APL management using big data
  • Using data to evaluate the clinical impact of genomic alterations

Collaboration between HOVON and UK AML NCRI Group

SWG members have been involved in this collaboration on a novel, AI-based prognostic scoring system.

It involves newly diagnosed AML patients who are over 60 years old being treated with intensive chemotherapy and allo-SCT in prospective randomized trials.

Multi-center acute myeloid leukemia study

During 2023, work began on this multi-center AML study. The project's full title is: ‘Evaluation of the prognostic impact of subclonal FLT3-ITD mutations in acute myeloid leukemia (AML): a retrospective multi-center study on behalf of the EHA AML-SWG.’ So far, eight centers across Europe have agreed to participate.

You can find out more about the project and its current status by visiting:

Grants received by SWG-related networks or principal investigators

In February 2023, the multi-center acute myeloid leukemia study (above) was selected for funding with an EHA ‘seeding grant.’

Other social and public EHA-related activities

EHA educational activities

  • Master class on AML (Konstanze Döhner).
  • Podcasts on AML.
  • Lighting the Flame program.


EHA's 2023 Congress was held in Frankfurt, Germany.

In addition to the activities outlined above, SWG members took part in the following sessions.

Education session on novel therapeutic approaches in acute myeloid leukemia

Three presentations were delivered as part of this session:

  • ‘Immunotherapy approaches in AML: Potential and challenges’
  • ‘Targeted therapies in AML’ (Paresh Vyas)
  • ‘Maintenance treatment concepts in AML’

Highlight session on ‘How I treat AML in special circumstances'

Two presentations were delivered as part of this session: 

  • ‘Pregnancy in AML’ (Nicola Stefano Fracchiolla)
  • ‘Management of organ complications and toxicities with novel drugs’ (Christoph Röllig)

EHA-SRH-SHRTM Balkan Hematology Tutorial

The topic of this tutorial was ‘AML: Diagnostic work-up, prognostic factors, and risk classification.’

It was delivered by K. Döhner in Bucharest, on March 17–18, 2023.

19th ELN Symposium with 22nd KLN Symposium

A HARMONY/HARMONY Plus Session took place on April 18, 2023.

This session included the following presentations:

  • ‘The HARMONY Foundation – Value for public organizations’ (K. Döhner)
  • ‘AML Data visualization on the HARMONY Platform’ (L. Bullinger)

EHA-Balkan Hematology Day 2023

This event took place in Belgrade, Serbia, on October 12, 2023. It included presentations on:

  • ‘Acute Myeloid Leukemia: Diagnosis and Therapy’ (K. Döhner)
  • ‘Acute Myeloid Leukemia: First line therapies’ (B. Huntly)

Joint Session SSH/EHA

This event took place in Basel, Switzerland, during November, 2023.

It included a presentation by K. Döhner on ‘Impact of molecular genetics for the management of AML.’

ELN Breakfast Meeting at the 65th ASH Annual Meeting

During this event, which took place on December 10, 2023, L. Bullinger and K. Döhner delivered a presentation on ‘HARMONY/HARMONY Plus: update and next steps.’